Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens

Abstract

Marek's disease (MD) remains a continual threat to the poultry industry worldwide as the MD virus continues evolving in virulence. MD has been controlled primarily by intensive use of vaccines since 1969. Based on the antigenic and pathogenic differences of the viruses that the vaccines were derived from, commercially available MD vaccines are classified into three categories, MDV-1, -2, and -3 vaccines. This study was designed to compare the protective efficacy of MDV-1 (CVI988/Rispens) and MDV-3 (HVT) vaccines against challenge of a very virulent plus strain of Marek's disease virus (vv+MDV) in experimental and commercial egg-layer lines of chickens under controlled experimental conditions. The two experimental lines (63 and 72) of chickens carry a uniform MHC B*2 haplotype and are known to differ in resistance to MD. One of the two commercial egg-layer lines (WL and BL) segregates for three MHC haplotypes (B*2, B*15, and B*21); the other is unclear. MD incidences of the unvaccinated groups of both experimental lines and both commercial lines were 100% or close to 100% induced by the vv+MDV, 648A. Survived day patterns of the unvaccinated groups significantly differed between the two experimental lines, but did not between the two commercial lines, which suggested the two experimental lines do differ in resistance to MD but not between the two commercial lines. At manufacturers’ recommended vaccine dosage, two HVTs conveyed comparable protection for the MD resistant line 63 chickens as did both CVI988/Rispens used in this study. The two HVTs also conveyed comparable protection for both commercial lines of chickens as did one of two CVI988/Rispens (CVI988/Rispens-A). At a 2000PFU uniform dose, HVT and CVI988/Rispens again conveyed comparable protection for the MD resistant experimental line of chickens. The findings suggest vaccine protective efficacy is modulated by factors including the types and the sources of vaccines and the genetic backgrounds of chickens. The findings also suggest HVT delivers equal protection in MD resistant lines of chickens as does the industry-recognized golden standard of MD vaccine, CVI988/Rispens.